Resistance to PGE2 inhibition of PWM-stimulated lymphocytes from neoplastic patients

Giacomo Nicocia, Claudia Garipoli, Mario Venza, Isabella Venza, Antonino Sottile, Vincenzo Pitini, Diana Teti

Research output: Contribution to journalArticlepeer-review


PGE2 treatment of mononuclear cells from patients with different types of neoplasias was unable to decrease either the number of plaque-forming cells or the expression of CD71 and CD25 in PWM-driven cultures. In contrast, in previous studies, PGE2 inhibited these parameters in cultured mononuclear cells from normal volunteers. Surgical treatment of cancer patients did not modify the lymphocyte sensitivity to PGE2 after 1 week, but at 2 and 6 mouths after therapeutical treatment, the inhibition values of the parameters studied were almost similar or very similar to those of normal lymphocytes. The reduction of PGE2 sensitivity in cancer patients was related to the increase of PGE2 levels and, probably, to a PGE2 receptor saturation. A restoration of PGE2-induced inhibition some months after therapy could be due to the decrease in PGE2 levels and to receptor unsaturation.

Original languageEnglish
Pages (from-to)115-123
Number of pages9
JournalClinical Immunology and Immunopathology
Issue number2
Publication statusPublished - May 1998


  • Cancer patients
  • Cultures
  • Lymphocytes
  • PGE

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Resistance to PGE2 inhibition of PWM-stimulated lymphocytes from neoplastic patients'. Together they form a unique fingerprint.

Cite this